Roche’s Risdiplam Meets Primary Endpoint in pivotal FIREFISH Trial in Infants who have SMA Type 1

23 January 2020

Risdiplam is a small molecule drug that specifically modulates how effectively the SMN2 gene is used to make SMN protein. Roche have put out a press release showing positive endpoint results from their FIREFISH study of risdiplam with infants aged 1-7 months who have SMA Type 1.

Read the press release

Read more about risdiplam